NDAORALCAPSULEPriority Review
Approved
Sep 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COGNEX (tacrine hydrochloride) is an oral small-molecule cholinesterase inhibitor approved in 1993 for Alzheimer's disease. It works by increasing acetylcholine levels in the brain to improve cognitive function. The drug represents one of the earliest pharmacologic treatments for cognitive decline in dementia patients.
LOE Approaching
With LOE approaching and 30% competitive pressure, the brand team is likely in maintenance mode with minimal growth investment and stable headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on COGNEX offers minimal career growth given its LOE-approaching status and zero linked job postings. Roles on this product are primarily defensive, focused on maintaining market share against generics and newer competitors rather than driving innovation.
Brand ManagerField Sales Representative
Worked on COGNEX at Shionogi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.